President of Research
Parker Institute for Cancer Immunotherapy & Medici Therapeutics
San Francisco, California, United States
Ira Mellman (FAACR, FAIO) is President of Research at the Parker Institute of Cancer Immunotherapy (PICI) and CSO of Medici Therapeutics, both in San Francisco. An expert in cancer vaccines, Ira is a member of the US National Academy of Sciences and former VP of Cancer Immunology at Genentech, Sterling Professor of Cell Biology & Immunobiology at Yale Medical School, and a postdoctoral fellow with Ralph Steinman at The Rockefeller University. Ira is best known for fundamental advances in cell biology (particularly the discovery of endosomes) and for applying these insights to elucidate the mechanisms of antigen processing by dendritic cells and the basis of PD-1/PD-L1 inhibition; Ira was also responsible for devising the Cancer Immunity Cycle framework. At Genentech, his group was responsible for having discovered and developed four FDA-approved cancer agents, including the anti-PD-L1 antibody atezolizumab (Tecentriq®). Ira is the recipient of the 2025 Richard Smalley award of the Society for the Immunotherapy of Cancer and the Lloyd J. Old Award for Cancer Immunotherapy.
Disclosure information not submitted.
Keynote Address: The Coming Renaissance of Cancer Immunotherapy
Wednesday, June 25, 2025
5:30pm - 6:15pm East Coast USA Time
